NASDAQ$MIRM
Mirum Pharmaceuticals Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Mirum Pharmaceuticals reported its fourth quarter and full-year 2024 financial results, highlighting significant growth in product sales and progress in its clinical pipeline.
Mirum Pharmaceuticals reported strong financial performance in Q4 2024, with total revenue reaching $99.4 million and a net loss of $23.79 million. The company also provided positive full-year 2025 guidance, expecting continued revenue growth and positive cash flow.
- Total net product sales for 2024 reached $336.4 million, exceeding expectations.
- The VISTAS study for volixibat in PSC is expected to complete enrollment in the second half of 2025, with topline data anticipated in 2026.
- CTEXLI (chenodiol) received US approval for cerebrotendinous xanthomatosis.
- The company ended 2024 with $292.8 million in cash, cash equivalents, and investments, indicating a strong financial position.
Headline financials
Revenue & EPS history
Mirum Pharmaceuticals · Revenue · Quarterly
$99.4M
Revenue by segment
Mirum Pharmaceuticals · $29.1M total across 1 segment · Q1 2023
- Net Product Sales$29.1M—100.0%
Forward guidance
Mirum Pharmaceuticals expects continued revenue growth in 2025, with global net product sales projected to be between $420 million and $435 million, and anticipates achieving positive cash flow.
Tailwinds
- Expected continued revenue growth in 2025.
- Anticipated global net product sales of approximately $420 million to $435 million in 2025.
- Expectation of positive cash flow in 2025.
- VISTAS study in primary sclerosing cholangitis (PSC) expected to complete enrollment in second half 2025.
- Expect to initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in 2025.
Headwinds
- No specific negative forward guidance was provided in the report.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+2.9%
Avg return
30 days after
59%
16 / 27 earnings
Positive
+26.4%
Q2 2022
Best reaction
-16.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.0% | +0.2% | -11.7% | |
| Q4 2025 | -15.1% | -19.2% | -18.6% | |
| Q3 2025 | -1.4% | -1.8% | -3.5% | |
| Q1 2025 | +9.9% | +9.8% | +12.5% | |
| Q4 2024 | -7.0% | -10.5% | -9.0% | |
| Q3 2024 | +5.6% | +6.9% | +1.6% | |
| Q2 2024 | +1.8% | +14.3% | +5.0% | |
| Q1 2024 | -0.3% | -4.4% | -3.2% | |
| Q4 2023 | -3.0% | -3.1% | -15.2% | |
| Q3 2023 | +5.6% | +5.6% | +12.6% | |
| Q2 2023 | +6.1% | +2.1% | +6.1% | |
| Q1 2023 | -8.3% | -7.9% | -7.9% | |
| Q4 2022 | -1.1% | -4.7% | +5.1% | |
| Q3 2022 | -16.2% | -19.7% | -24.1% | |
| Q2 2022 | +26.4% | +18.0% | +7.4% | |
| Q1 2022 | +7.1% | -4.4% | +7.0% | |
| Q4 2021 | +3.3% | +1.5% | +29.5% | |
| Q3 2021 | +0.1% | -1.2% | -7.9% | |
| Q2 2021 | +0.5% | -4.0% | +23.0% | |
| Q1 2021 | -1.4% | -6.3% | -10.8% | |
| Q4 2020 | +6.0% | +14.3% | +10.2% | |
| Q3 2020 | +11.6% | +16.9% | +48.0% | |
| Q2 2020 | +13.0% | +15.3% | -4.3% | |
| Q1 2020 | +0.1% | +6.2% | +10.8% | |
| Q4 2019 | +8.1% | -10.5% | +25.7% | |
| Q3 2019 | -0.1% | +4.0% | +22.6% | |
| Q2 2019 | -9.0% | -10.3% | -31.5% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro